World Wires · story 27046 · unverified · 1 source(s)

SEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma Study

Publication provides new evidence from clinical trial that Vaccinex’s pepinemab appears to support a coordinated immune attack on cancer.

Open in the desk

Coverage

• SEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma Study GlobeNewswire: public companies · tier D · clear net · 2026-10-07 12:30 UTC

What this site indexes